GSK Announces Depemokimab Late-Breaking Data Presented At ERS Show A 54% Reduction In Severe Asthma Exacerbations; SWIFT-1 And SWIFT-2 Phase III Data Show Depemokimab Delivered Significant And Clinically Meaningful Reduction In Exacerbations Over 52 Weeks Versus Placebo Plus Standard Of Care, In Duplicate Studies
Portfolio Pulse from Benzinga Newsdesk
GSK presented late-breaking data at the ERS showing that their drug Depemokimab significantly reduces severe asthma exacerbations by 54% in Phase III trials. The SWIFT-1 and SWIFT-2 studies demonstrated meaningful reductions over 52 weeks compared to placebo.
September 09, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Depemokimab has shown a 54% reduction in severe asthma exacerbations in Phase III trials, indicating a strong potential for market success and positive impact on stock prices.
The successful Phase III trial results for Depemokimab suggest a significant advancement in asthma treatment, likely leading to increased investor confidence and a positive impact on GSK's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100